• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

    11/14/24 4:00:05 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $QNCX alert in real time by email
    SC 13G/A 1 qncx1015241sc13ga2.htm AMENDMENT NO. 2

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

     

    SCHEDULE 13G/A

     

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Quince Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

     

     

    22053A107

    (CUSIP Number)

     

     

     

     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

     

    x       Rule 13d-1(c)

     

    ¨       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 7 pages 
     

     

    CUSIP No.  22053A107

     

    13G/A Page 2 of 7 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0%

     

    12

    type of reporting person

     

    OO

     

     

     Page 2 of 7 pages 
     

     

    CUSIP No. 22053A107

     

    13G/A Page 3 of 7 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0%

     

    12

    type of reporting person

     

    IN

     

     

     Page 3 of 7 pages 
     

     

    CUSIP No. 22053A107

     

    13G/A Page 4 of 7 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) o

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY

    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting

    Person with

    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0%

     

    12

    type of reporting person

     

    pN

     

     

     Page 4 of 7 pages 
     

     

    Item 1(a).Name of Issuer:

     

    Quince Therapeutics, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    611 Gateway Boulevard, Suite 273, South San Francisco, CA 94080

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP (“Tang Capital Management”); Kevin Tang, the manager of Tang Capital Management; and Tang Capital Partners, LP (“Tang Capital Partners”).

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Tang Capital Partners is a Delaware limited partnership.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 22053A107

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)       Amount Beneficially Owned:

     

    Tang Capital Management. Tang Capital Management beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Kevin Tang. Kevin Tang beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 0 shares of the Issuer’s Common Stock.

     

    (b)Percent of Class:

     

    Tang Capital Management 0%
    Kevin Tang 0%
    Tang Capital Partners 0%

     

     Page 5 of 7 pages 
     

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 6 of 7 pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: November 14, 2024  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    TANG CAPITAL MANAGEMENT, LLC

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 7 of 7 pages

     

     

     

    Get the next $QNCX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QNCX

    DatePrice TargetRatingAnalyst
    3/24/2025$10.00Outperform
    Oppenheimer
    More analyst ratings

    $QNCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      9/3/24 5:38:44 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      8/22/24 5:51:16 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      8/21/24 6:38:07 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in the rare neurodegenerative disease Ataxia-Telangiectasia (A-T) has reached an important milestone as enrollment now exceeds 75% with a total of 65 participants randomized in the study's targeted 86 participants in the six to nine year-old primary analysis population. Key Phase 3 NEAT clinical trial enrollment highlights to date include: A total of 76 participants have been enr

      6/3/25 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

      Plan to potentially conclude enrollment early for Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T) to align topline results with existing cash runway Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the first quarter ended March 31, 2025. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "In light of current cash runway and with the goal of maximizing a capital efficient development plan, Quince has made the strategic business de

      5/13/25 8:00:00 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics to Present at Citizens Life Sciences Conference

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking place in New York City on Wednesday, May 7, 2025 beginning at 3:30 p.m. Eastern Time. A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event. About Quince Therapeutics

      4/30/25 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    SEC Filings

    See more
    • SEC Form 8-K filed by Quince Therapeutics Inc.

      8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

      6/5/25 4:12:42 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Quince Therapeutics Inc.

      10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)

      5/13/25 8:40:57 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

      5/13/25 8:01:26 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ryan Una S

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      6/6/25 5:52:41 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Benatti Luca

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      6/6/25 5:38:57 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Senner Christopher J.

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      6/6/25 5:36:21 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Quince Therapeutics with a new price target

      Oppenheimer initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $10.00

      3/24/25 8:40:42 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Financials

    Live finance-specific insights

    See more
    • Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors (the "Board") unanimously approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince's common stock. The dividend distribution will be made on April 17, 2023, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on April 5, 2024.

      4/5/23 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

      SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

      11/14/24 4:00:05 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Quince Therapeutics Inc.

      SC 13D - Quince Therapeutics, Inc. (0001662774) (Subject)

      11/13/24 9:17:26 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

      SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

      8/6/24 8:04:44 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Leadership Updates

    Live Leadership Updates

    See more
    • Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, to the company's Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince's SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. Dr. Mauro Magn

      1/23/25 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company's Board of Directors. "We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni's caliber to our Board of Directors," said David Lamond, chairperson of Quince's Board of Directors. "With expertise that spans the continuum from translational to registrational studies and regulatory agency negotiation in several rare diseases, we lo

      2/15/24 7:00:00 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Appoints Dr. Charles S. Ryan as President

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company's corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S.p.A., the international integration of financial and operational activities and ongoing business operations of Quince. Dirk Thye, M.D., Quince's Chief Executive Officer, said, "Charles is a valuable addition to our management team. His considera

      9/6/23 7:00:00 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care